NeuBase Therapeutics, Inc. (NBSE)


-0.00 (-0.27%)
Symbol NBSE
Price $0.182
Beta 0.851
Volume Avg. 0.46M
Market Cap 6.153M
Shares () -
52 Week Range 0.1206-1.45
1y Target Est -
DCF Unlevered NBSE DCF ->
DCF Levered NBSE LDCF ->
ROE -54.86% Strong Sell
ROA -58.91% Strong Sell
Operating Margin -
Debt / Equity 40.38% Neutral
P/E -0.19 Neutral
P/B 0 Neutral


Consensus EPS

Upgrades & Downgrades

Latest NBSE news

Dr. Dietrich A. Stephan Ph.D.
NASDAQ Capital Market

NeuBase Therapeutics, Inc., a pre-clinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders, and cancer and oncology applications. Its lead programs include NT0100, a PATrOL enabled anti-gene for Huntington's disease; NT0200, a PATrOL enabled anti-gene for myotonic dystrophy type 1; NT0300, a PATrOL-enabled therapeutic treatment to target the mutated KRAS gene. NeuBase Therapeutics, Inc. is headquartered in Pittsburgh, Pennsylvania.